Glucuronidation of the soyabean isoflavones genistein and daidzein by human liver is related to levels of UGT1A1 and UGT1A9 activity and alters isoflavone response in the MCF-7 human breast cancer cell line☆
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
The soyabean isoflavones genistein and daidzein, which may protect against some cancers,
cardiovascular disease and bone mineral loss, undergo substantial Phase 2 metabolism,
predominantly glucuronidation. We observed a correlation between rates of metabolism
of marker substrates of specific UGTs and rates of glucuronidation of genistein and
daidzein in vitro by a panel of human liver microsomes, demonstrating that UGT1A1
and UGT1A9, but not UGT1A4, make a major contribution to the metabolism of these isoflavones
by human liver. These findings were substantiated by observations that recombinant
human UGT1A1 and UGT1A9, but not UGT1A4, catalysed the production of the major glucuronides
of both genistein and daidzein in vitro. Recombinant human UGT1A8 also metabolised
both genistein and daidzein, whereas UGT1A6 was specific to genistein and UGTs 2B7
and 2B15 were inactive, or only marginally active, with either isoflavone as substrate.
The intestinal isoform UGT1A10 metabolised either both isoflavones or genistein only,
depending on the commercial supplier of the recombinant enzyme, possibly as a result
of a difference in amino acid sequence, which we were unable to confirm. Daidzein
(16 microM) increased cell death in the MCF-7 human breast cancer cell line and this
effect was reversed by glucuronidation. In view of a well-characterised functional
polymorphism in UGT1A1, these observations may have implications for inter-individual
variability in the potential health-beneficial effects of isoflavone consumption.